104
A. Antony and J.-H. Boo
50. Salgin S, Salgin U, Bahadir S (2012) Zeta potentials and isoelectric points of biomolecules:
the effects of ion types and ionic strengths. Int J Electrochem Sci 7:12404–12414
51. Milolajczyk A et al (2015) Zeta potential for metal oxide nanoparticles: a predictive model
developed by a nano-quantitative structure—property relationship approach. Chem Mater
27:2400–2407
52. Toropov AA et al (2018) Towards the development of global nano-quantitative structureproperty relationship models: zeta potentials of metal oxide nanoparticles. Nanomater
8:243–257
53. Acosta LS et al (2011) Biocompatible metal-oxide nanoparticles: nanotechnology improvement
of conventional prosthetic acrylic resins. J Nanomater: 1–8. http://dx.doi.org/10.1155/2011/
941561
54. Stavis SM, Fagan JA, Stopa M, Liddle JA (2018) Nanoparticle manufacturing—heterogeneity
through processes to products. ACS Appl Nanomater 1:4358–4385
55. White MA, Johnson JA, Koberstein JT, Turro NJ (2006) Toward the syntheses of universal
ligands for metal oxide surfaces: controlling surface functionality through click chemistry. J
Am Chem Soc 128:11356–11357
56. Yi G, Son J, Yoo J, Park C, Koo H (2018) Application of click chemistry in nanoparticle
modification and its targeted delivery. Biomater. Res. 22:13–20. https://doi.org/10.1186/s40
824-018-0123-0
57. Dekkers S et al (2016) Towards a nanospecific approach for risk assessment. Regul Toxicol
Pharmacol 80:46–59
58. Simko M, Mattsson MO (2014) Interactions between nanosized materials and the brain. Curr
Med Chem 21:4200–4214
59. Bankier C et al (2018) A comparison of methods to assess the antimicrobial activity of nanoparticle combinations on bacterial cells. PLOS ONE 13(2): 1 e0192093 (1–13). https://doi.org/
10.1371/journal.pone.0192093
60. http://users.aber.ac.uk/hlr/mpbb/index_files/Page299.html
61. Ibrahim SF, Gvd Engh (2007) Flow cytometry and cell sorting. Adv Biochem Engin/Biotechnol
106:19–39
62. Barry AL, Coyle MB, Thornsberry C, Gerlach EH, Hawkinson RW (1979) Methods of
measuring zones of inhibition with the bauer kirby disk susceptibility test. J Clinical Microbiol
10:885–889
63. http://microchemlab.com/test/zone-inhibition-test-antimicrobial-activity
64. Arakha M et al (2015) Antimicrobial activity of iron oxide nanoparticle upon modulation of
nanoparticle-bacteria interface. Sci Rep 5:14813–14825
65. Zhang XQ et al (2012) Interactions of nanomaterials and biological systems: implications to
personalized nanomedicine. Adv Drug Deliv Rev 64:1363–1384
66. Deng ZJ et al (2009) Differential plasma protein binding to metal oxide nanoparticles.
Nanotechnol. 20:455101–455109
67. Gold K, Slay B, Knackstedt M, Gaharwar AK (2018) Antimicrobial activity of metal and
metal-oxide based nanoparticles. Adv Therap 1:1700033–1700045
68. Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K (2014) Antimicrobial
activity of the metals and metal oxide nanoparticles. Mater Sci Eng, C 44:278–284
69. Zunita M, Makertihartha IGBN, Saputra FA, Syaifi YS, Wenten IG (2018) Metal oxide based
antibacterial membrane. Mater Sci Eng 395:012021–012029
70. Arias LS et al (2018) Iron oxide nanoparticles for biomedical applications: a perspective on
synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics 7: 46–78
71. Hoseinzadeh E et al (2017) A review on nano-antimicrobials: metal nanoparticles, methods and
mechanisms. Curr Drug Metabol 18. https://doi.org/10.2174/1389200217666161201111146
72. http://www.mfds.go.kr/eng/index.do
73. http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf
74. https://www.fda.gov/default.htm
75. https://ec.europa.eu/info/departments/joint-research-centre_en
A. Antony and J.-H. Boo
50. Salgin S, Salgin U, Bahadir S (2012) Zeta potentials and isoelectric points of biomolecules:
the effects of ion types and ionic strengths. Int J Electrochem Sci 7:12404–12414
51. Milolajczyk A et al (2015) Zeta potential for metal oxide nanoparticles: a predictive model
developed by a nano-quantitative structure—property relationship approach. Chem Mater
27:2400–2407
52. Toropov AA et al (2018) Towards the development of global nano-quantitative structureproperty relationship models: zeta potentials of metal oxide nanoparticles. Nanomater
8:243–257
53. Acosta LS et al (2011) Biocompatible metal-oxide nanoparticles: nanotechnology improvement
of conventional prosthetic acrylic resins. J Nanomater: 1–8. http://dx.doi.org/10.1155/2011/
941561
54. Stavis SM, Fagan JA, Stopa M, Liddle JA (2018) Nanoparticle manufacturing—heterogeneity
through processes to products. ACS Appl Nanomater 1:4358–4385
55. White MA, Johnson JA, Koberstein JT, Turro NJ (2006) Toward the syntheses of universal
ligands for metal oxide surfaces: controlling surface functionality through click chemistry. J
Am Chem Soc 128:11356–11357
56. Yi G, Son J, Yoo J, Park C, Koo H (2018) Application of click chemistry in nanoparticle
modification and its targeted delivery. Biomater. Res. 22:13–20. https://doi.org/10.1186/s40
824-018-0123-0
57. Dekkers S et al (2016) Towards a nanospecific approach for risk assessment. Regul Toxicol
Pharmacol 80:46–59
58. Simko M, Mattsson MO (2014) Interactions between nanosized materials and the brain. Curr
Med Chem 21:4200–4214
59. Bankier C et al (2018) A comparison of methods to assess the antimicrobial activity of nanoparticle combinations on bacterial cells. PLOS ONE 13(2): 1 e0192093 (1–13). https://doi.org/
10.1371/journal.pone.0192093
60. http://users.aber.ac.uk/hlr/mpbb/index_files/Page299.html
61. Ibrahim SF, Gvd Engh (2007) Flow cytometry and cell sorting. Adv Biochem Engin/Biotechnol
106:19–39
62. Barry AL, Coyle MB, Thornsberry C, Gerlach EH, Hawkinson RW (1979) Methods of
measuring zones of inhibition with the bauer kirby disk susceptibility test. J Clinical Microbiol
10:885–889
63. http://microchemlab.com/test/zone-inhibition-test-antimicrobial-activity
64. Arakha M et al (2015) Antimicrobial activity of iron oxide nanoparticle upon modulation of
nanoparticle-bacteria interface. Sci Rep 5:14813–14825
65. Zhang XQ et al (2012) Interactions of nanomaterials and biological systems: implications to
personalized nanomedicine. Adv Drug Deliv Rev 64:1363–1384
66. Deng ZJ et al (2009) Differential plasma protein binding to metal oxide nanoparticles.
Nanotechnol. 20:455101–455109
67. Gold K, Slay B, Knackstedt M, Gaharwar AK (2018) Antimicrobial activity of metal and
metal-oxide based nanoparticles. Adv Therap 1:1700033–1700045
68. Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K (2014) Antimicrobial
activity of the metals and metal oxide nanoparticles. Mater Sci Eng, C 44:278–284
69. Zunita M, Makertihartha IGBN, Saputra FA, Syaifi YS, Wenten IG (2018) Metal oxide based
antibacterial membrane. Mater Sci Eng 395:012021–012029
70. Arias LS et al (2018) Iron oxide nanoparticles for biomedical applications: a perspective on
synthesis, drugs, antimicrobial activity, and toxicity. Antibiotics 7: 46–78
71. Hoseinzadeh E et al (2017) A review on nano-antimicrobials: metal nanoparticles, methods and
mechanisms. Curr Drug Metabol 18. https://doi.org/10.2174/1389200217666161201111146
72. http://www.mfds.go.kr/eng/index.do
73. http://www.egg2012.de/tl_files/pdf/Paper/EGG2012_C6_1_Park_presentation_slides.pdf
74. https://www.fda.gov/default.htm
75. https://ec.europa.eu/info/departments/joint-research-centre_en